1 recruiting, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow IL-2 (Aldesleukin): new trials by email Literature Review of IL-2 (Aldesleukin) trials Research Report on IL-2 (Aldesleukin)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease IL-2 (Aldesleukin), Semaglutide Plus IL-2, Placebo - Alzheimer Dementia (AD) | Phase 1 / Phase 2 | Recruiting | The Methodist Hospital Research Institute | 30 | 2026-09-01 | 2026-09-23 |
| T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR - Kita-kyushu Lung Cancer Antigen 1, Human | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2022-03-08 | 2025-12-02 |
Alzheimer Disease (1) · Carcinoma (1) · Inflammation (1) · Neoplasm Metastasis (1) · Triple Negative Breast Neoplasms (1)
National Cancer Institute (NCI) (1) · The Methodist Hospital Research Institute (1)
United States (2)